tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2025 Nov;19(11):e70190.
doi: 10.1111/irv.70190. Burden of Severe Disease Associated With Influenza, SARS-CoV-2 and RSV in Spain During the 2024-2025 Winter Season
Daniel Aguilar Figueroa[SUP] 1 [/SUP], Gloria Pérez-Gimeno[SUP] 2 3 [/SUP], Olivier Núñez[SUP] 2 3 [/SUP], Susana Monge[SUP] 2 4 [/SUP]; SiVIRA Surveillance and Vaccine Effectiveness Working Group
Affiliations
We estimated the burden of influenza, SARS-CoV-2 and RSV from patients hospitalized with acute respiratory infection systematically tested between weeks 40/2024 and 20/2025 in Spain. The hospitalization rate per 100,000 was highest for influenza [67.5 (95% Confidence Interval: 52.5-87.3)] followed by RSV [46.6 (35.4-62.2)] and SARS-CoV-2 [15.8 (10.2-24.6)]. Hospitalization rates peaked in ≥ 60-year-olds and < 5-year-olds, ICU admissions in < 1-year-olds and deaths in ≥ 80-year-olds. Hospitalization for SARS-CoV-2 at 80-85 years was comparable to influenza at 60-65 years, potentially signaling the appropriateness of increasing the COVID-19 vaccination age cut-off. RSV prevention appeared a priority in < 5-year-olds but substantial preventive potential was identified in the elderly.
Keywords: COVID‐19; RSV; burden of disease; influenza; sentinel surveillance.
. 2025 Nov;19(11):e70190.
doi: 10.1111/irv.70190. Burden of Severe Disease Associated With Influenza, SARS-CoV-2 and RSV in Spain During the 2024-2025 Winter Season
Daniel Aguilar Figueroa[SUP] 1 [/SUP], Gloria Pérez-Gimeno[SUP] 2 3 [/SUP], Olivier Núñez[SUP] 2 3 [/SUP], Susana Monge[SUP] 2 4 [/SUP]; SiVIRA Surveillance and Vaccine Effectiveness Working Group
Affiliations
- PMID: 41250923
- DOI: 10.1111/irv.70190
We estimated the burden of influenza, SARS-CoV-2 and RSV from patients hospitalized with acute respiratory infection systematically tested between weeks 40/2024 and 20/2025 in Spain. The hospitalization rate per 100,000 was highest for influenza [67.5 (95% Confidence Interval: 52.5-87.3)] followed by RSV [46.6 (35.4-62.2)] and SARS-CoV-2 [15.8 (10.2-24.6)]. Hospitalization rates peaked in ≥ 60-year-olds and < 5-year-olds, ICU admissions in < 1-year-olds and deaths in ≥ 80-year-olds. Hospitalization for SARS-CoV-2 at 80-85 years was comparable to influenza at 60-65 years, potentially signaling the appropriateness of increasing the COVID-19 vaccination age cut-off. RSV prevention appeared a priority in < 5-year-olds but substantial preventive potential was identified in the elderly.
Keywords: COVID‐19; RSV; burden of disease; influenza; sentinel surveillance.